Skip to main content
Veterinary Medicines

ANTISHMANIA, 300 mg/ml, solution for injection for dogs.

Authorised
  • Meglumine antimonate

Product identification

Medicine name:
ANTISHMANIA, 300 mg/ml, solution for injection for dogs.
ANTISHMANIA SOLUTION INJECTABLE POUR CHIENS
Active substance:
  • Meglumine antimonate
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Meglumine antimonate
    300.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Solution for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP51DX01
Authorisation status:
  • Valid
Authorised in:
  • France
Package description:
  • box containing 5 vials of 5 ml
  • box containing 10 vials of 5 ml

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Fatro S.p.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Fatro S.p.A.
Responsible authority:
  • National Veterinary Medicines Agency
Authorisation number:
  • FR/V/7989990 5/2016
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0232/001
Concerned member states:
  • France
  • Greece

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/04/2023
Download
French (PDF)
Published on: 26/05/2023

Package Leaflet

English (PDF)
Published on: 11/04/2023
Download

Labelling

English (PDF)
Published on: 11/04/2023
Download

Package Leaflet and Labelling

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 11/05/2023

eu-PUAR-antishmania--300-mg-ml--solution-for-injection-for-dogs.-en.pdf

English (PDF)
Published on: 11/04/2023
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."